The safety and efficacy of INTERCEPT™ Blood System-processed plasma has been supported by haemovigilance programmes and several clinical trials. INTERCEPT plasma has been demonstrated to effectively support patients with acquired coagulation factor deficiencies resulting from liver disease or liver transplant, those undergoing therapeutic plasma exchange (TPE) due to thrombotic thrombocytopenic purpura (TTP), and those undergoing liver transplantation.

Haemovigilance programmes tracking the routine use of over 200,000 INTERCEPT-treated plasma units have demonstrated therapeutic efficacy with an adverse event profile consistent with untreated plasma.